Research to Advance Vaccine Safety (NIH, R01)

The purpose of this funding is to support research that will contribute to the overall understanding of vaccine safety.

This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety such as:
 1) physiological and immunological responses to vaccines and vaccine components
 2) how genetic variations affect immune/physiological responses that may impact vaccine safety
 3) identification of risk factors and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines
4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources such as passive reporting systems or healthcare databases
5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety.

( Clinical trials will not be supported.)

Eligibility: Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Budget:  Budgets are not limited but need to reflect the actual needs of the proposed project.

Duration: The maximum project period is 5 years.

Deadline: October 5 2017

Full details: https://grants.nih.gov/grants/guide/pa-files/PA-15-312.html

NLM Express Research Grants in Biomedical Informatics (R01)

Purpose and areas of focus 

• support for innovative research in biomedical informatics
• informatics problem areas in the application domains of health care, public health, basic biomedical research, bioinformatics, biological modeling, translational research and health information management in disasters
• informatics projects of interest to NLM involve the application of computer and information sciences concepts to information problems in a biomedical domain
• also supports research projects focused on biomedical (rather than informatics) research questions, but approached exclusively by novel or advanced informatics techniques applied to information and data produced by others.
• high priority on innovation in the research

Scope of NLM's research interests

• Information & knowledge processing
• Advanced information retrieval, knowledge discovery in databases, discovery mining, and other techniques for in silico discovery
• Incorporation of machine intelligence into decision tools and resources
• Modeling and presentation approaches to enhance decisions, learning or understanding
• Innovative approaches for ensuring accuracy, privacy and security of clinical and biomedical research data

Budget - $250,000 per year in direct costs.

Period - maximum project period is 4 years

Eligibility - Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.


Deadline - October 5th 2016 

Full details - http://grants.nih.gov/grants/guide/pa-files/PAR-13-300.html 

NIH Grant - Partnerships for Countermeasures Against Select Pathogens (R01)

This grant provides funding for milestone-driven preclinical research that will advance the development and/or production of lead therapeutics, vaccines or medical diagnostics for select Emerging Infectious Diseases/Pathogens. 

All projects must have investment by at least one industry participant. Industry means a pharmaceutical, biotechnology, bioengineering, or chemical company. 

The list of Emerging Infectious Diseases/Pathogens is here - https://www.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/Pages/CatA.aspx. 

The list  includes  dengue, melioidosis, diarrheagenic E.coli and chikungunya virus.

Study can be in the areas of - 

Therapeutics

Must focus on previously-identified, well-characterized, candidate leads or lead candidate series and/or targets for the following select pathogen categories:

Vaccines 

Projects must focus on development of a candidate vaccine aligned with one of the following categories:

Multivalent/Universal Vaccines

Therapeutic Vaccines

Vaccines with Small Market Potential


Diagnostics 

Proposed diagnostics must align to one of the following programmatic diagnostic priorities:

Diagnostics that Facilitate Antibacterial Stewardship

Diagnostics for Zika Virus (ZIKV)


Budget - Budgets for direct costs of up to $750,000 per year may be requested.


Duration -  The maximum project period is 5 years.


Eligibility - Foreign (non-USA) Institutions are eligible to apply.


Deadline - October 3, 2016


Full details - http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-034.html 

NIH - Modeling of Infectious Disease Agent Study Research Projects (R01)

Purpose

To support innovative research that will develop and apply computational tools and methods for modeling interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. 

The models should be useful to researchers, policymakers, or public health workers who want to better understand and respond to infectious diseases. 

This research opportunity encourages applications from institutions/organizations that propose to provide the scientific and public health communities better resources, knowledge, and tools to improve their ability to prepare for, identify, detect, control, and prevent the spread of infectious diseases caused by naturally occurring or intentionally released pathogens, including those relevant to biodefense.


Details 

Deadline   - June 5th 2016

Budget available - budgets are not limited but need to reflect the actual needs of the proposed project.

Full information - http://grants.nih.gov/grants/guide/pa-files/PA-16-107.html 

NIH- National Heart, Lung and Blood Institute - Phase II and phase III randomized clinical trials

The purpose of this grant is to fund investigator-initiated multi-site randomized controlled clinical trials. The trials may address any research question related to the mission and goals of the NHLBI and may test clinical or behavioral interventions. The grant is appropriate for studies to conduct phase II and phase III randomized clinical trials where participants are recruited from multiple sites.

Examples of diseases covered NHLBI - 
Anaemia
Bronchitis 
Diabetic Heart Disease
Metabolic Syndrome

Deadline - June 5th 2016

More details - http://grants.nih.gov/grants/guide/pa-files/PAR-13-128.html

Foreign Institutions are eligible to apply